Search results for " DRUG DELIVERY."

showing 10 items of 182 documents

Loading and release of the complex [Pt(DTBTA)(DMSO)Cl]Cl·CHCl3 with the 2,2′-dithiobis(benzothiazole) ligand into mesoporous silica and studies of an…

2018

Abstract Synthetic delivery systems have great potential for overcoming problems associated with systemic toxicity that accompanies chemotherapy with the use of cisplatin and family of platinum anticancer drugs. Mesoporous silicates have been studied in context of drug delivery and drug targeting. In this paper we report the studies of loading and release of a platinum complex, [Pt(DTBTA)(DMSO)Cl]Cl∙CHCl3 (1) where DTBTA = 2,2′-dithiobis(benzothiazole), that was recently synthesized and structurally characterized. Evaluation in vitro of antitumor activity against a human breast cancer cell line (MCF-7) showed a very potent activity of complex(1). Therefore, we thought to incorporate this co…

02 engineering and technologyMesoporous silica010402 general chemistry021001 nanoscience & nanotechnology01 natural sciencesControlled release0104 chemical sciencesInorganic ChemistryAntiproliferative activityControlled releaseLoadingMCM41Platinum(II) complexchemistry.chemical_compoundTargeted drug deliveryBenzothiazolechemistrySettore CHIM/03 - Chimica Generale E InorganicaDrug deliveryMaterials ChemistryPhysical and Theoretical Chemistry0210 nano-technologyCytotoxicityMesoporous materialConjugateNuclear chemistrySettore CHIM/02 - Chimica Fisica
researchProduct

Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment

2018

Standard of care for cancer is commonly a combination of surgery with radiotherapy or chemoradiotherapy. However, in some advanced cancer patients this approach might still remaininefficient and may cause many side effects, including severe complications and even death. Oncolytic viruses exhibit different anti-cancer mechanisms compared with conventional therapies, allowing the possibility for improved effect in cancer therapy. Chemotherapeutics combined with oncolytic viruses exhibit stronger cytotoxic responses and oncolysis. Here, we have investigated the systemic delivery of the oncolytic adenovirus and paclitaxel encapsulated in extracellular vesicles (EV) formulation that, in vitro, s…

0301 basic medicine3003Lung NeoplasmsCancer therapymedicine.medical_treatmentPharmaceutical ScienceOncolytic viruseschemistry.chemical_compoundpaclitaxelkeuhkosyöpä0302 clinical medicineMedicineMice Inbred BALB CExtracellular vesiclesCHEMOTHERAPYCombined Modality Therapy3. Good healthxenograft animal modelPaclitaxelLiver317 Pharmacy030220 oncology & carcinogenesisonkolyyttiset viruksetcancer therapyFemaleLung canceronkolyyttinen virushoitoOncolytic adenovirusEFFICIENCYPaclitaxelCancer therapy; Drug delivery; Extracellular vesicles; Lung cancer; Oncolytic viruses; Paclitaxel; Xenograft animal model; 30033122 CancersMice NudeXenograft animal modelta3111OVARIAN-CANCERVIROTHERAPY03 medical and health sciencesCell Line TumorAnimalsHumansVirotherapyLung cancerChemotherapyADENOVIRUS RECEPTORsyöpähoidotbusiness.industryta1182CancerENDOSTATINmedicine.diseaseta3122Antineoplastic Agents PhytogenicGENEOncolytic virusMODELlung cancer030104 developmental biologychemistryviroterapiaDrug deliveryCELLSdrug deliveryCancer researchbusinessOvarian cancersolunulkoiset vesikkelitSpleen
researchProduct

Ticket to Ride: Targeting Proteins to Exosomes for Brain Delivery.

2017

Exosomes represent an attractive vehicle for the delivery of biomolecules. However, mechanisms for loading functional molecules into exosomes are relatively unexplored. Here we report the use of the evolutionarily conserved late-domain (L-domain) pathway as a mechanism for loading exogenous proteins into exosomes. We demonstrate that labeling of a target protein, Cre recombinase, with a WW tag leads to recognition by the L-domain-containing protein Ndfip1, resulting in ubiquitination and loading into exosomes. Our results show that Ndfip1 expression acts as a molecular switch for exosomal packaging of WW-Cre that can be suppressed using the exosome inhibitor GW4869. When taken up by floxed …

0301 basic medicineBiocompatibilityRecombinant Fusion ProteinsGene ExpressionComputational biologyBiologyExosomesPermeabilityCell LineExtracellular VesiclesMice03 medical and health sciencesDrug Delivery SystemsDrug DiscoveryGeneticsAnimalsMolecular BiologyPharmacologyIntegrasesbusiness.industryImmunogenicityMembrane ProteinsRNABrainProteinsMicrovesiclesBiotechnologyProtein Transport030104 developmental biologyTargeted drug deliveryBlood-Brain BarrierCommentaryMolecular MedicineOriginal ArticleNasal AbsorptionCarrier ProteinsGenetic EngineeringbusinessMolecular therapy : the journal of the American Society of Gene Therapy
researchProduct

Imatinib-Loaded Micelles of Hyaluronic Acid Derivatives for Potential Treatment of Neovascular Ocular Diseases

2018

In this work, new micellar systems able to cross corneal barrier and to improve the permeation of imatinib free base were prepared and characterized. HA-EDA-C-16, HA-EDA-C-16-PEG, and HA-EDA-C-16-CRN micelles were synthesized starting from hyaluronic acid (HA), ethylenediamine (EDA), hexadecyl chains (C-16), polyethylene glycol (PEG), or L-carnitine (CRN). These nanocarriers showed optimal particle size and mucoadhesive properties. Imatinib-loaded micelles were able to interact with corneal barrier and to promote imatinib transcorneal permeation and penetration. In addition, a study was conducted to understand the in vitro imatinib inhibitory effect on a choroidal neovascularization process…

0301 basic medicineCell SurvivalDrug CompoundingPharmaceutical ScienceAdministration Ophthalmic02 engineering and technologyPolyethylene glycolMicellePermeabilityCell LinePolyethylene GlycolsCornea03 medical and health scienceschemistry.chemical_compoundocular drug delivery hyaluronic acid polymeric micelles imatinib transcorneal permeation ocular neovascular diseasesCarnitinehemic and lymphatic diseasesDrug DiscoveryHyaluronic acidPEG ratiomedicineocular drug delivery; hyaluronic acid; polymeric micelles; imatinib; transcorneal permeation; ocular neovascular diseasesAnimalsHumansHyaluronic AcidParticle SizeProtein Kinase InhibitorsneoplasmsMicellesDrug CarriersEndothelial CellsImatinibPermeation021001 nanoscience & nanotechnologyEthylenediaminesIn vitroChoroidal NeovascularizationDrug Liberation030104 developmental biologychemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoBiophysicsImatinib MesylateMolecular Medicinelipids (amino acids peptides and proteins)CattleNanocarriers0210 nano-technologymedicine.drug
researchProduct

Albumin-Folate Conjugates for Drug-targeting in Photodynamic Therapy.

2016

Photodynamic therapy (PDT) is based on the cytotoxicity of photosensitizers in the presence of light. Increased selectivity and effectivity of the treatment is expected if a specific uptake of the photosensitizers into the target cells, often tumor cells, can be achieved. An attractive transporter for that purpose is the folic acid receptor α (FRα), which is overexpressed on the surface of many tumor cells and mediates an endocytotic uptake. Here, we describe the synthesis and photobiological characterization of polar β-carboline derivatives as photosensitizers covalently linked to folate-tagged albumin as the carrier system. The particles were taken up by KB (human carcinoma) cells within …

0301 basic medicineCell Survivalmedicine.medical_treatmentSerum albuminPhotodynamic therapy010402 general chemistry01 natural sciencesBiochemistryPhotodynamic therapyCell Line03 medical and health sciencesFolic AcidmedicineHumansFolate Receptor 1Physical and Theoretical ChemistryCytotoxicityAlbumin conjugatesPhotosensitizing AgentsbiologyChemistryOtras Ciencias QuímicasCiencias QuímicasSerum Albumin BovineGeneral Medicine0104 chemical sciencesB-carbolines030104 developmental biologyTargeted drug deliveryBiochemistryPhotochemotherapyDrug deliveryDrug deliverybiology.proteinFolate receptor 1PhotosensitizationPhototoxicityCIENCIAS NATURALES Y EXACTASConjugateCarbolinesPhotochemistry and photobiology
researchProduct

Nanoparticle delivery to metastatic breast cancer cells by nanoengineered mesenchymal stem cells

2017

We created a 3D cell co-culture model by combining nanoengineered mesenchymal stem cells (MSCs) with the metastatic breast cancer cell line MDA-MD-231 and primary breast cancer cell line MCF7 to explore the transfer of quantum dots (QDs) to cancer cells. First, the optimal conditions for high-content QD loading in MSCs were established. Then, QD uptake in breast cancer cells was assessed after 24 h in a 3D co-culture with nanoengineered MSCs. We found that incubation of MSCs with QDs in a serum-free medium provided the best accumulation results. It was found that 24 h post-labelling QDs were eliminated from MSCs. Our results demonstrate that breast cancer cells efficiently uptake QDs that a…

0301 basic medicineCellGeneral Physics and Astronomyquantum dotsspheroidslcsh:Chemical technologylcsh:TechnologyFull Research Paper03 medical and health sciences3D cell culturemedicineNanotechnologycancerlcsh:TP1-1185General Materials ScienceElectrical and Electronic Engineeringlcsh:Scienceskin and connective tissue diseases3D cell culturemesenchymal stem cellslcsh:TChemistryMesenchymal stem cellCancermedicine.diseaseMetastatic breast cancerlcsh:QC1-999Nanoscience030104 developmental biologymedicine.anatomical_structureTargeted drug deliveryCell cultureCancer cellCancer researchlcsh:Qlcsh:PhysicsBeilstein Journal of Nanotechnology
researchProduct

Aptamers as smart ligands for nano-carriers targeting

2016

The development of enhanced drug delivery systems is one of the most attractive fields of pharmaceutical sciences, as some of the highly effective chemo/biotherapeutics for cancer treatment can not be administrated due to their high toxicities for normal cells or low stability in physiological media. However, drugs that are currently not administrable will become valuable if specific cell-targeted drug carriers can protect the normal cells from adverse effects and also improve drug pharmacokinetics. Aptamers are attractive and promising biomaterials developed with high affinity and specificity against numerous valuable targets. They could act similar to monoclonal antibodies (mAbs), and off…

0301 basic medicineChemistryNano carriersAptamerNanotechnology02 engineering and technology021001 nanoscience & nanotechnologyAnalytical ChemistryCancer treatment03 medical and health sciences030104 developmental biologyTargeted drug deliveryDrug deliveryPharmaceutical sciencesNanocarriers0210 nano-technologyDrug carrierSpectroscopyTrAC Trends in Analytical Chemistry
researchProduct

Nano-engineered skin mesenchymal stem cells: potential vehicles for tumour-targeted quantum-dot delivery

2017

Nanotechnology-based drug design offers new possibilities for the use of nanoparticles in imaging and targeted therapy of tumours. Due to their tumour-homing ability, nano-engineered mesenchymal stem cells (MSCs) could be utilized as vectors to deliver diagnostic and therapeutic nanoparticles into a tumour. In the present study, uptake and functional effects of carboxyl-coated quantum dots QD655 were studied in human skin MSCs. The effect of QD on MSCs was examined using a cell viability assay, Ki67 expression analysis, and tri-lineage differentiation assay. The optimal conditions for QD uptake in MSCs were determined using flow cytometry. The QD uptake route in MSCs was examined via fluore…

0301 basic medicineEndosomeGeneral Physics and Astronomyquantum dots02 engineering and technologylcsh:Chemical technologyEndocytosislcsh:TechnologyFull Research PaperFlow cytometry03 medical and health sciencesmedicineNanotechnologyendocytosislcsh:TP1-1185General Materials ScienceCD90stem cell differentiationViability assayMicropinocytosisElectrical and Electronic Engineeringlcsh:Sciencemesenchymal stem cellsmedicine.diagnostic_testlcsh:TChemistryMesenchymal stem cell021001 nanoscience & nanotechnologylcsh:QC1-999Cell biologyNanoscience030104 developmental biologyTargeted drug deliverylcsh:Q0210 nano-technologylcsh:PhysicsBeilstein Journal of Nanotechnology
researchProduct

Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous Leukemia cell growth

2017

Despite Imatinib (IM), a selective inhibitor of Bcr-Abl, having led to improved prognosis in Chronic Myeloid Leukemia (CML) patients, acquired resistance and long-term adverse effects is still being encountered. There is, therefore, urgent need to develop alternative strategies to overcome drug resistance. According to the molecules expressed on their surface, exosomes can target specific cells. Exosomes can also be loaded with a variety of molecules, thereby acting as a vehicle for the delivery of therapeutic agents. In this study, we engineered HEK293T cells to express the exosomal protein Lamp2b, fused to a fragment of Interleukin 3 (IL3). The IL3 receptor (IL3-R) is overexpressed in CML…

0301 basic medicineMedicine (miscellaneous)PharmacologyEngineered exosomeExosomesInterleukin 3Antineoplastic AgentMiceHEK293 Cellhemic and lymphatic diseasesDrug CarrierPharmacology Toxicology and Pharmaceutics (miscellaneous)Drug CarriersChronic myeloid leukemiaMyeloid leukemiaChronic myeloid leukemia; Drug delivery; Drug resistance; Engineered exosomes; Interleukin 3; Animals; Antineoplastic Agents; Cell Line Tumor; Cell Proliferation; Disease Models Animal; Drug Carriers; Exosomes; HEK293 Cells; Heterografts; Humans; Imatinib Mesylate; Leukemia Myelogenous Chronic BCR-ABL Positive; Mice; Receptors Interleukin-3; Treatment Outcome3. Good healthTreatment OutcomeImatinib MesylateHeterograftsHeterograftResearch Papermedicine.drugHumanEngineered exosomesAntineoplastic Agents03 medical and health sciencesIn vivoCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineAnimalsHumansneoplasmsInterleukin 3.Interleukin 3Cell Proliferationbusiness.industryAnimalImatinibmedicine.diseaseMicrovesiclesReceptors Interleukin-3ExosomeDisease Models AnimalHEK293 Cells030104 developmental biologyImatinib mesylateDrug resistanceCancer cellDrug deliverybusinessChronic myelogenous leukemia
researchProduct

Chemoresistance and chemosensitization in cholangiocarcinoma

2017

One of the main difficulties in the management of patients with advanced cholangiocarcinoma (CCA) is their poor response to available chemotherapy. This is the result of powerful mechanisms of chemoresistance (MOC) of quite diverse nature that usually act synergistically. The problem is often worsened by altered MOC gene expression in response to pharmacological treatment. Since CCA includes a heterogeneous group of cancers their genetic signature coding for MOC genes is also diverse; however, several shared traits have been defined. Some of these characteristics are shared with other types of liver cancer, namely hepatocellular carcinoma and hepatoblastoma. An important goal in modern onco…

0301 basic medicinePharmacologybile ductschemotherapydrug delivery systems0302 clinical medicineChemosensitizationantineoplastic agentsmolecular biologyReceptorhumansreceptor protein-tyrosine kinasesmedia_commonapoptosisgene expression regulationbile duct neoplasmsDrug Resistance Multipletargeted therapiesGene Expression Regulation Neoplasticmultiplebiliary cancer; chemotherapy; liver cancer; multidrug resistance; targeted therapies; antineoplastic agents; apoptosis; bile duct neoplasms; bile ducts; cell survival; cholangiocarcinoma; drug delivery systems; drug resistance multiple; drug resistance; neoplasm; epithelial cells; gene expression regulation neoplastic; genetic therapy; humans; protein kinase inhibitors; receptor protein-tyrosine kinases; signal transduction; treatment outcome; molecular medicine; molecular biology030220 oncology & carcinogenesisHepatocellular carcinomabiliary cancerLiver cancercholangiocarcinomaTyrosine kinasesignal transductionDrugHepatoblastomamedia_common.quotation_subjectcell survivalPharmacological treatmentliver cancer03 medical and health sciencesmultidrug resistancemedicinemolecular medicinedrug resistancebusiness.industrymedicine.diseaseepithelial cellsneoplasticprotein kinase inhibitors030104 developmental biologyDrug Resistance NeoplasmCancer researchtreatment outcomebusinessneoplasmgenetic therapy
researchProduct